Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | Case report

Ustekinumab/vedolizumab

Treatment failure and various toxicities: 7 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Albshesh A, et al. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine 12: No. 7, Apr 2023. Available from: URL: https://doi.org/10.3390/jcm12072503 Albshesh A, et al. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine 12: No. 7, Apr 2023. Available from: URL: https://​doi.​org/​10.​3390/​jcm12072503
Metadaten
Titel
Ustekinumab/vedolizumab
Treatment failure and various toxicities: 7 case reports
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-46351-6

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Pantoprazole

Case report

Zoledronic-acid

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Multiple drug